$0.010000
00.00%
Last update: 3:55 PM
15 minutes delayed
Comments
Loading...
Evofem Biosciences
EVFMOTCQB
Evofem Biosciences (OTC:EVFM) Stock, Analyst Ratings, Price Targets, Forecasts
Evofem Biosciences Inc has a consensus price target of $1.81 based on the ratings of 5 analysts. The high is $4 issued by HC Wainwright & Co. on August 15, 2022. The low is $0.5 issued by Stifel on October 13, 2022. The 3 most-recent analyst ratings were released by Stifel, HC Wainwright & Co., and Morgan Stanley on October 13, 2022, August 15, 2022, and July 15, 2022, respectively. With an average price target of $1.75 between Stifel, HC Wainwright & Co., and Morgan Stanley, there's an implied 17400.00% upside for Evofem Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
HC Wainwright & Co.
Morgan Stanley
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Evofem Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 12/13/2023 | Buy Now | — | Laidlaw & Co. | Yale Jen | — | Downgrade | Buy → Hold | Get Alert |
| 10/13/2022 | Buy Now | 4900% | Stifel | Annabel Samimy | $375 → $62.5 | Downgrade | Buy → Hold | Get Alert |
| 08/15/2022 | Buy Now | 39900% | HC Wainwright & Co. | Raghuram Selvaraju | $250 → $500 | Maintains | Buy | Get Alert |
| 07/15/2022 | Buy Now | 7400% | Morgan Stanley | Jeffrey Hung | $250 → $93.75 | Maintains | Underweight | Get Alert |
| 06/02/2022 | Buy Now | 34900% | Laidlaw & Co. | Yale Jen | → $437.5 | Initiates | → Buy | Get Alert |
| 05/25/2022 | Buy Now | 19900% | Piper Sandler | David Amsellem | $3750 → $250 | Maintains | Overweight | Get Alert |
| 05/11/2022 | Buy Now | 19900% | Morgan Stanley | Jeffrey Hung | $1068.75 → $250 | Maintains | Underweight | Get Alert |
| 05/10/2022 | Buy Now | 85400% | Morgan Stanley | Jeffrey Hung | $71.25 → $1068.75 | Maintains | Underweight | Get Alert |
| 04/12/2022 | Buy Now | 5600% | Morgan Stanley | Jeffrey Hung | $7.95 → $8.55 | Maintains | Underweight | Get Alert |
| 03/04/2022 | Buy Now | 5200% | Morgan Stanley | Jeffrey Hung | $7.5 → $7.95 | Maintains | Underweight | Get Alert |
| 11/16/2021 | Buy Now | 19900% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
| 10/21/2021 | Buy Now | 24900% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
| 10/14/2021 | Buy Now | 7900% | Morgan Stanley | Jeffrey Hung | — | Downgrade | Equal-Weight → Underweight | Get Alert |
| 08/12/2021 | Buy Now | 9900% | Morgan Stanley | Jeffrey Hung | — | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Evofem Biosciences (EVFM) stock?
The latest price target for Evofem Biosciences (OTCQB:EVFM) was reported by Laidlaw & Co. on December 13, 2023. The analyst firm set a price target for $0.00 expecting EVFM to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Evofem Biosciences (EVFM)?
The latest analyst rating for Evofem Biosciences (OTCQB:EVFM) was provided by Laidlaw & Co., and Evofem Biosciences downgraded their hold rating.
When was the last upgrade for Evofem Biosciences (EVFM)?
There is no last upgrade for Evofem Biosciences
When was the last downgrade for Evofem Biosciences (EVFM)?
The last downgrade for Evofem Biosciences Inc happened on December 13, 2023 when Laidlaw & Co. changed their price target from N/A to N/A for Evofem Biosciences Inc.
When is the next analyst rating going to be posted or updated for Evofem Biosciences (EVFM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evofem Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evofem Biosciences was filed on December 13, 2023 so you should expect the next rating to be made available sometime around December 13, 2024.
Is the Analyst Rating Evofem Biosciences (EVFM) correct?
While ratings are subjective and will change, the latest Evofem Biosciences (EVFM) rating was a downgraded with a price target of $0.00 to $0.00. The current price Evofem Biosciences (EVFM) is trading at is $0.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.